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Abstract The aim of this study was to investigate the ef-
fects of simvastatin, a competitive inhibitor of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, on
inflammation and glomerulosclerosis in Adriamycin
(ADR)-induced nephropathy. Male Sprague-Dawley rats
were randomly divided into control, ADR nephrosis, and
simvastatin-treated ADR nephrosis groups. ADR nephrop-
athy was induced by a single-tail intravenous injection of
ADR (6.5 mg/kg). Anti-inflammatory effects of simvastatin
were studied by evaluating the expression of the inflam-
matory mediators interleukin-1 beta (IL-1β), transforming
growth factor-β1 (TGF-β1), and transcription factor nuclear
factor kappa B (NF-κB). In addition, renal function, serum
lipid levels, and histopathology were compared between
groups. Simvastatin significantly decreases IL-1β and TGF-
β1 expression and NF-κB activation, accompanied by
significant attenuation of glomerulosclerosis and renal
function at 12 weeks after ADR injection, and these changes
occurred in the absence of lowering of serum lipids. These
results suggest that overexpression of inflammation in the
renal region may contribute to development of glomerulo-
sclerosis in ADR-induced-nephropathy rats, and simvastatin
treatment prevented glomerulosclerosis independent of the
lipid-lowering effects. The beneficial effect of simvastatin
might be mediated by the effect of anti-inflammatory action
through a reduction of NF-κB activation, and IL-1β and
TGF-β expression.
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ELISA enzyme linked immunosorbent assay
H&E hematoxylin and eosin
PAS periodic acid-Schiff
GSI glomerulosclerosis index
RT-PCR reverse transcription polymerase chain
reaction
GN glomerulonephritis
GBM glomerular basement membrane
TGF-β1 transforming growth factor beta 1
NF-κB nuclear factor kappa B
Introduction
Massive proteinuria and hyperlipidemia are important
manifestations of minimal-change nephrotic syndrome
(MCNS). Protein and lipids escaping through damaged
glomeruli could “stress” intrinsic renal cells [1]. It has been
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reported that interleukin-1 beta (IL-1β) can only be re-
leased by cells under stress conditions [2]. IL-1β is a pri-
mary proinflammatory cytokine, which is proposed as a
major mediator in both the initiation and progression of
glomerulosclerosis [3]. Glomerulosclerosis is the end
stage of MCNS; however, few studies have been per-
formed to elucidate the role of IL-1β on the development
of glomerulosclerosis in MCNS.
Statins are competitive inhibitors of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA) reductase, the key enzyme
that regulates synthesis of cholesterol from mevalonic acid by
suppressing the conversion of HMG-CoA [4]. Because of this
activity, the clinical use of statins has produced a significant
reduction in cardiovascular-related morbidity and mortality
in patients with established cardiovascular disease and hyper-
cholesterolemia [5, 6]. In addition, several beneficial effects
of statins have been described in experimental models of
renal disease, including streptozotocin-induced diabetic
nephropathy [7], puromycin-induced nephrosis [8], and
chronic cyclosporin A (CsA)-induced nephropathy [9]. Nev-
ertheless, the effect of statins in a rat model of Adriamycin
(ADR) induced nephropathy has not been reported, which
characterized experimental analogue of human MCNS.
Although it is widely accepted that the clinical benefit
obtained with statins is a direct result of their lipid-lowering
properties, there is still debate as to whether the additional
so-called pleiotropic effects of statins contribute to the
clinical outcome in renal disease or whether all beneficial
effects of statins are due to lowering plasma lipids. Recent-
ly, accumulating evidence has suggested that statins have
pleiotropic effects independent of plasma lipid lowering
[10].
Hence, this study was performed to investigate the role
of renal-region inflammation on the development of
glomerulosclerosis in ADR-induced-nephropathy rats and
whether simvastatin had an anti-inflammatory effect inde-
pendent of plasma lipid lowering in the model.
Materials and methods
Animals
Male Sprague-Dawley rats (4–5 weeks old) with an average
body mass of 130 g (provided by the Center for
Experimental Animals, Research Institute of Surgery, Third
Military Medical University, China) were housed in a room
at a constant temperature of 22±2°C, humidity 55–56%,
with a 12-h light–dark cycle and free access to standard
pellet chow and water. All animal procedures were in
accordance with the guidelines for the care and use of
laboratory animals approved by the Third Military Medical
University, China.
Experimental protocol and sample collection
Rats were randomly divided into control, ADR nephrosis,
and simvastatin-treated ADR nephrosis groups. ADR
nephrosis was induced by a single-tail intravenous injection
of ADR (6.5 mg/kg body weight; diluted to 50% with 0.9%
saline; Pharmacia, Italia). The control rats were injected
with a comparable volume of 0.9% saline. Simvastatin at
3 mg/kg body weight dissolved in a 0.06% solution of
0.9% saline was administered once a day by gavage. This
dosage was selected because it does not affect serum lipids
levels in Sprague-Dawley rats [11]. Control and ADR-
nephrosis rats received 0.9% saline 5 ml/kg once a day by
gavage. Treatment was started 6 days after ADR injection
and continued throughout the experiment. On the 0, 6, 13,
27, 55, and 83 days, the animals were placed in individual
metabolic cages for 24-h urine collection. During urine
collection, rats were deprived of food to avoid contamina-
tion of the urine but were allowed free access to water.
Under chloral hydrate anesthesia (300 mg/kg intraperito-
neally), the rats were sacrificed at 14, 28, 56, and 84 days
after ADR injection. Blood was collected from the femoral
artery, serum was prepared via centrifugation at 850 g for
15 min at 4°C, and stored at −20°C until further analysis.
Renal tissue was topical hypothermia perfused with cold
0.9% saline 10–15 ml until renal tissue became pale, and
then was removed. The upper pole of the right kidney was
fixed in 10% formaldehyde for routine histological exami-
nation and immunohistochemical study, and part of the
renal cortex was fixed in 3% glutaraldehyde for transmis-
sion electron microscopy examination. After separating
renal medulla, the middle proportion of the right kidney
was kept in liquid nitrogen for ribonucleic acid (RNA)
analysis, and the lower pole of the right kidney was
homogenized for cytokine analysis. The renal homogenate
(10% w/v) was suspended in phosphate-buffered saline
(PBS) solution. After centrifugation at 2,500 g at 4°C for
15 min, the supernatant was collected and stored at −20°C.
Biochemical analysis
The 24-h urinary protein excretion was measured using the
Coomassie brilliant blue method. Serum albumin (ALB),
total cholesterol (TC), triglyceride (TG), low-density
lipoprotein (LDL), and creatinine (Cr) were measured using
an automatic biochemical analyzer (Dimension RxL, Dade
Behring Inc., USA).
Histopathological examination
The fixed tissue specimens were dehydrated in graded
alcohol, cleared in toluene, and embedded in paraffin.
Paraffin sections (3 μm) were stained with hematoxylin and
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eosin (H&E) and periodic acid-Schiff (PAS). Glomerulo-
sclerosis was defined as disappearance of cellular elements
from the tufts, collapse of the capillary lumen, and folding
of the glomerular basement membrane with entrapment of
amorphous material [12]. Severity of glomerulosclerosis
was evaluated using an index score that included the
percent of glomeruli showing sclerosis and the degree of
extension of the glomerulosclerosis within the glomeruli, as
described previously by Rodriguez et al. [13]. Briefly,
glomeruli were graded from 0 to +4: grade 0, normal; grade
1, <25% involvement of the glomerular tuft; grade 2, 25–
50% involvement; grade 3, 50–75% involvement; and
grade 4, sclerosis occupying >75% of the glomerular tuft.
The glomerulosclerosis score was obtained as follows: [(1×
number of glomeruli with +1)+(2×number of glomeruli
with +2)+(3×number of glomeruli with +3)+(4×number
of glomeruli with +4)]×100%/total number of glomeruli
examined. In each kidney specimen, approximately 30
glomeruli were examined in cortical and juxtamedullary
areas selected at random. Histopathological evaluation was
made in a blinded fashion by an investigator.
The renal cortex was immediately fixed in 3% glutaral-
dehyde in cacodylate buffer for 2 h, postfixed in 1%
osmium tetroxide for 1 h, dehydrated in graded ethanol,
washed in acetone, and embedded in Epon 812. Ultrathin
sections for ultrastructural examination were stained with
uranyl acetate and lead citrate and examined with a
transmission electron microscope (H-7600; Hitachi, Tokyo,
Japan) at 75 kV. Renal specimens at 2, 4, and 12 weeks
from each group were observed.
Immunohistochemical analysis of IL-1β and TGF-β1
Immunohistochemistry (two-step method) was used to ob-
serve IL-1β and TGF-β1 expression. In brief, renal cortical
paraffin sections (3 μm) were deparaffinized and rehy-
drated, treated with 0.3% H2O2 in methanol for 15 min to
quench endogenous peroxide activity, and boiled at 100°C
for 10 min in 10 mM citrate buffer (pH 6.0) to unmask anti-
gens. Sections were incubated with rabbit anti-rat IL-1β
antibody (working dilution 1:100; sc-7884, Santa Cruz,
USA) or rabbit anti-rat TGF-β1 (working dilution 1:100; sc-
146) at 4°C overnight, followed by horseradish-peroxidase-
labeled polymer conjugated to secondary goat anti-rabbit
antibody at 37°C for 30 min (PV-6001, Zhongshan, China).
Sections were visualized with diaminobenzidene (DAB)
reagent and counterstained with hematoxylin. PBS was
substituted for primary antibodies as negative control,
whereas the positive control was from confirmed positive
tissue specimens.
Quantification of TGF-β1 immunostaining was per-
formed by calculating the proportion of area occupied by
the brown staining in all glomeruli or tubular area per section
using the Image-Pro Plus System associated with a video
camera and computer, as described previously by Qin [14].
RNA isolation and reverse transcription polymerase chain
reaction (RT-PCR) examination
Total RNA was isolated from frozen kidney according to
the manufacturer’s protocol (R6311-01, Genemega, USA).
Gel electrophoresis and ethidium bromide staining confirmed
the purity and integrity of the samples. Quantification of RNA
was based on spectrophotometric analysis at 260/280 nm.
Then, 2 μg of total RNAwere reverse-transcribed with 0.5 μl
reverse transcriptase (DRR037S, TaKaRa, China) using ran-
dom 6 mers and oligo dT primer as primers in a 10 μl reaction
mixture following the manufacturers instructions. The com-
plementary deoxyribonucleic acid (cDNA) was used as a
template in Multiplex polymerase chain reaction (PCR) reac-
tion with housekeeping β-actin gene as an internal control.
PCR was performed in 25 μl of reaction solution con-
taining 0.25 mM deoxynucleoside triphosphate (dNTP),
1.5 mM magnesium chloride (MgCl2), 0.05 U Taq poly-
merase, 10 mM Tris hydrochloride (HCl) (pH 8.3), and
50 mM potassium chloride (KCl) (all from TIANGEN,
China), 50 pmol of each rat-specific oligonucleotide prim-
ers (all from Invitrogen, China) and reverse transcriptase
(RT) products (1/5 of RT reaction). IL-1β and β-actin
primers were designed from published rat sequences [15,
16]. They were as follows: for the IL-1β 5’ primer, 5’-
CTGTGACTCGTGGGATGATG-3’, and 3’ primer, 5’-
GGGATTTTGTCGTTGCTTGT-3’; and for the β-actin 5’
primer, 5’-TTCTACAATGAGCTGCGTGTGG-3’, and the
3’ primer, 5’-ATACCCAGGAAGGAAGGCTGGAAG-3’.
The sizes of the reaction products were 210 bp for IL-1β
and 539 bp for β-actin. PCR for IL-1β and β-actin were
performed according to the following cycle: the samples
were heated to 94°C for 4 min, followed by 30 temperature
cycles. Each cycle consisted of denaturation 94°C for
1 min, annealing 60°C for 1 min, and extension 72°C for
1 min. After 30 reaction cycles, the extension reaction was
continued for another 5 min.
PCR products were analyzed by electrophoresis on 1.5%
agarose gel containing 0.005% GoldView™, and the gels
were photographed under ultraviolet light. The bands were
visualized with Quantity One ChemiDocXRS (Bio-Rad,
USA) and quantified by image analysis software (Quantity
One). The relative intensity of bands for IL-1β was normal-
ized using the intensity ofβ-actin, calculated as the ratio of the
intensity values of each target product to that of β-actin.
Measurement of IL-1β in serum and kidney
The levels of IL-1β in serum and kidney were detected by
enzyme-linked immunosorbent assay (ELISA) kit (BMS630,
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Bender, Austria), with a detection limit of 4.4 pg/ml. All
specimens were assayed in duplicate according to the
instructions provided by the manufacturer.
Protein quantification by Western blotting
The nuclei extracts were isolated from renal cortex ac-
cording to the manufacturer’s protocol (K266, Bioision,
USA). Protein samples (75 μg/lane) were denatured and
subjected to electrophoresis on a 5% stacking and 10%
separating sodium dodecyl sulfate-polyacrylamide gel in a
Bio-Rad mini Protein II apparatus. Electrophoretic transfer
to polyvinylidine difluoride membrane was accomplished at
1 mA/cm2 membrane for 1 h in 48 mmol/l Tris, 39 mmol/l
glycine, 0.037% sodium dodecyl sulfate (SDS), and 20%
methanol. The membrane was then blocked with 5%
skimmed milk for 1 h at room temperature, followed by
two 5-min washes in TBST (Tris-buffered saline/0.1%
Tween-20). The membrane was incubated with primary
antibody against nuclear factor kappa B (NF-κB) p65
(ab31407, ABCAM, UK) at 1:600 dilution or against β-
actin (M611, JingMei, Chian) at 1:5,000 dilution at 4°C
overnight, followed by three 5-min washes in TBST. A goat
anti-rabbit horseradish-peroxidase-conjugated antibody
(GAR007, MultiScience, China) at 1:5,000 dilution was
added to the membrane for 1 h at room temperature,
followed by three 5-min washes in TBST. Finally, detection
procedures were performed using Chemiluminescent Sub-
strate Kit (LumiGLO, USA), and autoradiography was
performed on Quantity One ChemiDocXRS (Bio-Rad).
Band intensity volumes (% adjustment) were measured by
Quantity One software.
Statistical analysis
The software used for statistical analysis was SPSS for
Windows 13.0. Groups of data were analyzed using one-way
analysis of variance (ANOVA) followed by the Student–
Newman–Keuls test. Qualitative data was analyzed by the




As shown in Fig. 1, compared with the control rats, the
ADR-nephrosis rats developed marked proteinuria at
2 weeks after ADR injection, which peaked at 8 weeks,
and then decreased slightly at 12 weeks. The simvastatin-
treated nephrosis rats showed a trend toward a decrease in
24-h urinary protein excretion with a significant fall at 4
and 8 weeks, although without reaching significance at
12 weeks. Both untreated and simvastatin-treated nephrosis
rats exhibited marked hypoalbuminemia (Fig. 2a) and
hyperlipidemia (Fig. 2b–d). The level of serum albumin in
the simvastatin-treated group was higher than in the un-
treated group at 2, 4, 8, and 12 weeks and was significantly
higher at 8 weeks (P<0.01). There were no significant
differences found in serum TC, TG, and LDL between
untreated and simvastatin-treated nephrosis rats. Serum Cr
concentration in untreated nephrotic rats was higher
than in control rats at 8 and 12 weeks (P<0.05, P<0.01,
respectively). Serum Cr concentration in simvastatin-treated
rats did not significantly increase until 12 weeks when com-
pared with control rats and was lower than in untreated rats
(P<0.05) at 12 weeks (Fig. 2e). During the treatment period,
untreated and simvastatin-treated nephrotic rats gained weight
slowly when compared with the control rats; however,
simvastatin-treated nephrotic rats gained more weight than
untreated rats in the same experimental period (Fig. 2f).
Histopathological findings
Under light microscopy, kidneys from control rats were
histologically normal (Fig. 3a,d), and there were no obvious
lesions found in kidneys from untreated and simvastatin-
treated nephrosis rats at 2 and 4 weeks. Whereas untreated
rats demonstrated glomerulosclerosis and renal tubular in-
jury from 8 weeks, the renal injury had become increas-
ingly serious by 12 weeks. Glomerular changes consisted of
collapse of glomerular tufts, glomerular tufts adhering to
Fig. 1 Twenty-four-hour proteinuria levels after Adriamycin (ADR)
injection. Marked proteinuria developed at 2 weeks after injection,
peaked at 8 weeks, and then decreased slightly at 12 weeks. The
simvastatin-treated ADR-nephrosis rats showed a trend toward a
decrease in 24-h urinary protein excretion, with significant difference
at 4 and 8 weeks. Each group consisted of eight rats; values represent
mean ± standard error of mean. CTL control, ADR untreated ADR
nephrosis, SIMV simvastatin-treated ADR nephrosis. *P<0.01 vs.
control; #P<0.05, ΔP<0.01 vs. untreated ADR nephrosis in the same
experimental day, respectively
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Fig. 3 Light microscopy of renal tissues in control (a, d), untreated
nephrosis (b, e) and simvastatin-treated nephrosis (c, f) at 12 weeks
after Adriamycin injection (a–c, hematoxylin & eosin; d–f, periodic
acid-Schiff). The untreated nephrotic rats showed glomeruli with focal
segmental glomerulosclerosis (arrow). Magnification bars 50 μm
Fig. 2 Levels of serum albumin
(ALB), total cholesterol (TC),
triglycerides (TG), low-density
lipoprotein (LDL), creatinine
(Cr), and body weight. Each
group consisted of eight rats;
values represent mean ± stan-
dard error of mean. CTL con-
trol, ADR untreated ADR
nephrosis, SIMV simvastatin-
treated ADR nephrosis.. *P<
0.01, ▲P<0.05 vs. control;
ΔP<0.01, #P<0.05 vs. untreated
ADR nephrosis in the same
experimental day,
respectively
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Bowman’s space, and mild mesangial expansion. Consis-
tent with the high level of albuminuria, significant tubular
dilation associated with large proteinaceous casts and tubu-
lar atrophy were also noted. Glomerular and renal interstitial
injury were accompanied by patches of leukocyte infiltration
(Fig. 3b,e). In the nephrosis rats receiving simvastatin,
lesions were markedly reduced compared with untreated
rats (Fig. 3c,f). The untreated rats had higher glomeruloscle-
rosis indexes (8.40±2.33% vs. 0.78±0.28% in the control rats
at 8 weeks, P<0.01, and 15.65±4.75% vs. 0.96±0.34% in
the control rats at 12 weeks, P<0.01). Compared with the
untreated rats, treatment with simvastatin significantly atten-
uated the glomerulosclerosis index (5.19±2.04% at 8 weeks,
P<0.01, and 9.14±4.25% at 12 weeks, P<0.01).
Ultrastructural change
Compared with the control rats (Fig. 4a), in ADR-nephrosis
rats at 2 weeks, the normal arrangement of interdigitating
foot processes was lost and the foot processes broadened
(Fig. 4b); at 4 weeks, widespread fusion and effacement of
foot processes appeared (Fig. 4c). All changes observed
were limited to podocyte and glomerular basement mem-
brane, whereas endothelial and mesangial cells did not show
marked changes on electron microscopy, which is similar to
humanMCNS. At 12 weeks, untreated rats showed podocyte
swelling, cytoplasmic lysis, lipid drop deposition, and
mitochondria intracristal space expansion besides the fusion
and effacement of foot processes (Fig. 4d). Lesions in
simvastatin-treated rats were markedly reduced when com-
pared with untreated rats (Fig. 4e).
Expression of IL-1β
In control rats (Fig. 5a), only faint staining for IL-1β was
observed in renal tubular epithelial cells, and there was no
obvious increase in either untreated or simvastatin-treated
rats at 2 and 4 weeks. However, IL-1β expression in
untreated rat kidneys increased by 8 weeks and remarkably
so by 12 weeks (Fig. 5b), and IL-1β was found mainly in
glomerular cells and renal tubular epithelial cells, with
almost no positive renal interstitial expression. IL-1β ex-
pression in simvastatin-treated rats was substantially weaker
than in untreated rats in the same experimental day (Fig. 5c).
Compared with the control group, IL-1β messenger RNA
(mRNA) expression increased by 59.6% and 117.4% in the
untreated group at 8 and 12 weeks, and 33.7% and 60.0%
in simvastatin-treated group in the same experimental period,
respectively (Fig. 6). IL-1β levels in renal homogenate
supernatant and serum at 8 and 12 weeks were quantitatively
detected by ELISA (Table 1). No significant differences were
found between serum IL-1β concentrations in controls, un-
treated, and simvastatin-treated rats. However, renal concen-
tration of IL-1β increased by 36.3% and 84.5% in the
untreated group at 8 and 12 weeks and 20.1% and 44.6% in
the simvastatin-treated group in the same experimental day
compared with the control group, respectively.
Expression of TGF-β1 in kidney
As with IL-1β expression in the kidney, TGF-β1 expression
in untreated nephrotic rat kidneys increased at 8 weeks and
remarkably so by 12 weeks (Fig. 5e). Untreated rats had an
increased glomerulus and tubulus immunostaining for TGF-
β1 when compared with control rats at 12 weeks (untreated
13.44±1.83% vs. control, 1.65±0.28%, P<0.01; Fig. 5d).
Simvastatin treatment was associated with reduced immu-
nostaining for TGF-β1 when compared with untreated rats
at 12 weeks (8.57±1.26%, P<0.05 vs. untreated; Fig. 5f).
NF-κB p65 protein expression in renal cortex
To evaluate NF-κB activity, we examined nuclear p65
protein expression in renal cortex of rats at 12 weeks by
Fig. 4 Morphological change in the podocyte foot process under
transmission electron microscopy. Foot processes in the control rats
were tall and narrow (a). At 2 weeks after Adriamycin injection, foot
processes broadened (b). Fusion and effacement of foot processes was
observed at 4 weeks after Adriamycin injection (c). Fusion and
effacement of foot processes accompanying with podocyte swelling,
cytoplasmic lysis (arrow) and lipid drop deposition (arrowhead) and
mitochondria intracristal space expansion in the untreated rats at
12 weeks (d). Simvastatin-treated rats showed moderate fusion and
effacement of foot processes and no podocyte cytoplasm lysis (e).
Magnification bars 2 μm
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Western blotting (Fig. 7a). As shown in Fig. 7b, p65 levels
in untreated rats was significantly higher than those in
control and simvastatin-treated rats. Treatment with sim-
vastatin significantly decreased the level of p65.
Discussion
In this study, we used the ADR model of MCNS. A
single injection of ADR resulted in massive proteinuria,
Fig. 5 Immunostaining for interleukin-1 beta (IL-1β) in control (a),
untreated (b), and simvastatin-treated (c); and transforming growth
factor beta (TGF-β) in control (d), untreated (e) and simvastatin-
treated (f) rats at 12 weeks after Adriamycin injection. Magnification
bars 50 μm
Fig. 6 Renal messenger ribonucleic acid (mRNA) expression of
interleukin-1 beta (IL-1β) at 12 weeks by reverse transcriptase
polymerase chain reaction (RT-PCR). M molecular weight marker
(a). Lanes 1–3 control (CTL), Lanes 4–6 untreated Adriamycin (ADR)
nephrosis (ADR), Lanes 7–9 simvastatin-treated ADR nephrosis
(SIMV). IL-1β mRNA levels from RT-PCR relative to the housekeep-
ing gene, β-actin (b). Each group consisted of six rats; values
represent mean ± standard error of mean. *P<0.01, ▲P<0.05 vs.
control; ΔP<0.01 vs. untreated ADR nephrosis in the same experi-
mental day
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hypoalbuminemia, hyperlipidemia, and decreased renal
function, indicating progressive renal failure. We also noted
the development of focal segmental glomerulosclerosis and
renal tubular injury from 8 weeks to 12 weeks after ADR
injection, accompanied by increasing renal IL-1β, TGF-β1,
and NF-κB expression. In contrast, simvastatin treatment
reduced urinary protein excretion and prevented loss of renal
function while ameliorating glomerulosclerosis and renal
tubular injury in parallel with reduction of IL-1β, TGF-β1,
and NF-κB expression in glomerular and renal tubular cells.
Notably, these changes occurred in the absence of the
lowering of serum lipids, suggesting a direct renoprotective
effect of simvastatin on ADR-nephrosis rats.
MCNS was proposed to be a disorder of T-cell dysfunc-
tion by Shalhoub in 1974 [17]. Unlike inflammatory renal
glomerular diseases, which elicit a wide spectrum of inflam-
matory and metabolic activities, MCNS has no systemic
inflammation and no immune complex deposition in the
glomeruli. There was no increase in serum IL-1β, a proin-
flammatory cytokine that triggers inflammatory processes by
activating a wide range of inflammatory mediators, in our
ADR-nephrosis rats, which accords with pathobiology of
ADR nephrosis. Massive proteinuria and hyperlipidemia are
important manifestations of nephrotic syndrome, and protein
and lipids escaping through damaged glomeruli could
activate intrinsic renal cells to secret cytokines. By immu-
nohistochemistry, we found that IL-1β positive expression
was mainly located in glomerular and tubular cells but
almost never in renal interstitial cells. The finding that
intrinsic renal cells are the major source of IL-1β synthesis in
normal and diseased rat kidney [18, 19] is consistent with
these data. IL-1β can induce mesangial cell proliferation
and extracellular matrix production and activate parietal
cells of Bowman’s capsule and tubular and interstitial cells
to release additional chemokines, leading to invasion of the
urinary space and interstitial tissue by T cells, macrophages,
and fibroblasts. The resulting damage to parietal and
visceral epithelial cells and tubular interstitial tissue leads
to irreversible sclerosis [1]. Studies in murine crescentic
glomerulonephritis (GN) indicate that IL-1β is the major
proinflammatory cytokine-mediating glomerular injury
[20]. The benefits of inhibiting IL-1 using anti-IL-1 anti-
bodies [21], soluble IL-1 receptor, or IL-1-receptor antag-
onist [22] have been shown in experimental GN. Our data
revealed that increasing IL-1β expression accompanied
severe glomerulosclerosis and renal tubular cell injury in
untreated ADR-nephrosis rats, whereas mild and moderate
glomerulosclerosis and renal tubular cell injury with weak
IL-1β expression were found in the renal tissue of
simvastatin-treated ADR-nephrosis rats. Taken together,
strong upregulation of IL-1β expression, particularly in
Fig. 7 Expression of nuclear p65 protein in renal cortex by Western
blotting. Levels of nuclear p65 protein in control group (CTL),
untreated group [Adriamycin (ADR)], and simvastatin-treated group
(SIMV) (a). Nuclear p65 protein levels from Western blotting relative
to the housekeeping gene, β-actin (b). Each group consisted of six
rats; values represent mean ± standard error of mean. CTL control
group, ADR untreated group, SIMV simvastatin-treated group. *P<
0.01, ▲P<0.05 vs. control; ΔP<0.01 vs. untreated ADR nephrosis in
the same experimental day
Table 1 Interleukin-1 beta (IL-1β) levels in serum and renal tissue at glomerulosclerosis stage
Groups Serum (pg/ml) Renal homogenate supernatant (pg/ml)
Week 8 Week 12 Week 8 Week 12
CTL 39.35 (12.18–377.66) 54.45 (33.35–163.44) 424.18±93.81 422.17±104.19
ADR 84.34 (5.48–859.77) 117.04 (37.68–917.73) 578.03±96.16* 786.09±227.32**
SIMV 47.90 (24.99–310.09) 124.60 (10.36–295.74) 509.36±163.36 616.26±128.99*,***
H or F value 0.285 2.830 3.187 10.052
P value 0.867 0.243 0.062 0.001
Each group consisted of eight rats, the values in serum expressed as median and range, and the values in renal homogenate supernatant represent
mean ± standard error of mean
CTL control, ADR untreated Adriamycin (ADR) nephrosis, SIMV simvastatin-treated ADR nephrosis
*P<0.05, **P<0.01 vs. control; ***P<0.05 vs. untreated ADR nephrosis in the same experimental day
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glomerular areas and accompanying tubular damage, at
least, may be an important trigger for glomerulosclerosis in
ADR-induced nephrosis in rats. Simvastatin can attenuate
glomerulosclerosis, and its renoprotective effect may partly
contribute to decreased renal IL-1β expression. Impor-
tantly, simvastatin did not change plasma lipids levels in
our study. These data support the hypothesis that simvas-
tatin has anti-inflammatory and antiglomerulosclerotic
activities independent of plasma lipid lowering.
Simvastatin treatment reduced transcription factor NF-
κB activation in this study. NF-κB is a rapid-response tran-
scription factor that promotes expression of a number of
genes involved in inflammation, such as cytokines, chemo-
kines, and adhesion molecules [23]. A previous study
revealed that NF-κB plays a pivotal role in the pathophys-
iology of renal diseases [24]. In nephropathy, many factors
such as filtered albumin, LDL, and ox-LDL contribute to
NF-κB activation in renal cells [24, 25]. The constitutive
activation of the NF-κB pathway is often associated with
increased expression of a variety of inflammatory genes,
including IL-1β, which is activated by and activates NF-κB
[23]. This type of positive regulatory loop may amplify and
perpetuate local kidney inflammatory responses. A recent
study suggested that statins possess anti-inflammatory
properties that involve NF-κB inhibition [26]. Therefore,
we investigated the effect of simvastatin on NF-κB activa-
tion as reflected by p65 in the renal cortex. NF-κB exists in
the cytoplasm as a heterodimer of a 50-kDa (p50) and a 65-
kDa (p65) subunit associated with an inhibitory protein of
the IκB family. When cells are stimulated, the IκB
inhibitory protein is phosphorylated, and it dissociates from
the NF-κB heterodimer. Free NF-κB then translocates into
the nucleus and induces target gene expression [23]. We
found by Western blotting that simvastatin inhibited p65
expression in the nuclei of the renal cortex of nephrotic rats,
suggesting that simvastatin may down-regulate IL-1β
expression by inhibiting NF-κB activation.
TGF-β1 has been consistently suggested to play a key
role in the pathogenesis of glomerulosclerosis and tubu-
lointerstitial fibrosis in progressive renal disease. Our study
confirmed an increase in TGF-β1 expression in the untreated
nephrotic kidney and further demonstrated that this increase
was prevented by simvastatin.
Several lines of evidence indicate that statins reduce
proteinuria [25, 27, 28]. In our study, urinary protein excre-
tion was significantly reduced by simvastatin from 4 weeks
to 8 weeks; however, urinary protein excretion decreased in
both untreated and simvastatin-treated rats at 12 weeks, and
the degree of decrease in simvastatin-treated rats was less
than in untreated rats. MCNS is characterized by high
glomerular basement membrane (GBM) permeability sec-
ondary to diffuse fusion and effacement of podocyte foot
processes. With the development of glomerulosclerosis,
urinary protein excretion decreases because of the GBM
permeability decrease and less protein filtering. The degree
of urinary protein excretion decrease in simvastatin-treated
rats was less than in untreated rats at 12 weeks, which
indirectly demonstrated that simvastatin can ameliorate
glomerulosclerosis in ADR-induced-nephropathy rats.
Although we reported the renoprotective effect of sim-
vastatin onADR-induced-nephropathy rats for the first time, a
couple of questions remain to be answered. We intend to es-
tablish an inflammation model of ADR-induced-nephropathy
rats . We will then investigate the relationship between NF-κB
expression and simvastatin treatment in cultured cells to
further describe which molecular mechanisms are responsible
for glomerulosclerosis in this animal model and whether NF-
κB plays a central role in the mediation of the anti-inflam-
matory effect of simvastatin. We will use other methods such
as in situ hybridization to further delineate which cells are
responsible for the inflammatory effect and which cells are
influenced by simvastatin in ADR-induced-nephropathy rats.
Conclusion
Overexpression of inflammation in renal region may contri-
bute to development of glomerulosclerosis in ADR-induced-
nephropathy rats, and simvastatin treatment prevented
glomerulosclerosis, independent of the lipids-lowering ef-
fects. The beneficial effect of simvastatin might be mediated
by the effect of anti-inflammatory action through a reduction
of NF-κB activation, IL-1β and TGF-β expression. The
precise mechanisms of simvastatin’s renoprotective effect on
ADR induced-nephrosis rats remain further investigation.
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